CreativeOne Wealth LLC Has $407,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN

CreativeOne Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 49.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 776 shares of the biopharmaceutical company’s stock after buying an additional 256 shares during the quarter. CreativeOne Wealth LLC’s holdings in Regeneron Pharmaceuticals were worth $407,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $310,000. Prudential Financial Inc. grew its stake in Regeneron Pharmaceuticals by 6.5% during the second quarter. Prudential Financial Inc. now owns 61,317 shares of the biopharmaceutical company’s stock worth $32,191,000 after buying an additional 3,768 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Regeneron Pharmaceuticals by 1.4% during the second quarter. Charles Schwab Investment Management Inc. now owns 720,273 shares of the biopharmaceutical company’s stock worth $378,143,000 after buying an additional 9,938 shares in the last quarter. Tableaux LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at about $67,725,000. Finally, CenterBook Partners LP raised its position in shares of Regeneron Pharmaceuticals by 802.9% in the 2nd quarter. CenterBook Partners LP now owns 51,591 shares of the biopharmaceutical company’s stock valued at $27,085,000 after buying an additional 45,877 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares in the company, valued at $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Jason Pitofsky sold 431 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $779.09 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $81.88 billion, a PE ratio of 18.66, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $800.99. The business has a 50-day simple moving average of $634.75 and a two-hundred day simple moving average of $583.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The company had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same period in the previous year, the business posted $12.46 earnings per share. The business’s quarterly revenue was up .9% compared to the same quarter last year. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Thursday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.43%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on REGN shares. Jefferies Financial Group lifted their price objective on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research note on Wednesday, August 27th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research note on Friday, October 10th. Truist Financial initiated coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $798.00 price objective for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, November 24th. Finally, Hsbc Global Res raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $757.91.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.